Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study

By sjmartinez • May 8, 2025

Özgüroğlu M, Goldman JW, Chen Y, Garassino MC, Medic N, Mann H, Chugh P, Dalvi T, Paz-Ares L. Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. Future Oncol. 2025 May 7:1-13. doi: 10.1080/14796694.2025.2491297. Epub ahead of print. PMID: 40331625.

Tags: Adverse events, durvalumab, Extensive-stage small-cell lung cancer, health-related quality of life, Hematology/Oncology, immune checkpoint inhibitors, patient experience, patient-reported adverse events, patient-reported outcomes, Publications

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva[...]

The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate Cancer, and Beyond

Chauhan A, Hendifar AE, El-Haddad G, Soares HP, Herrmann K. The Equivalents Are Coming! Developing a Shared Nomenclature for Radiopharmaceutical Therapy of Neuroendocrine Tumors, Prostate[...]

Breast Implant-Associated Malignancies: Current Recommendations for Workup and Management

Fracol ME, Miranda RN, Tsao AS, Rodriguez MM, Nastoupil LJ, Young PA, Sherrod AE, LeBlanc DM, Hunsicker LM, Bacchi CE, Gabriel T, Myckatyn TM, Tanaka[...]